EbolaPhase 2NCT03031912
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
A Phase 2 study testing V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine and Saline in people with Ebola, run by Canadian Immunization Research Network at 1 site in Canada.
Trial summary
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. Read more about this study
- Who is it for?
- Ages 13 to 65 years
- Conditions the study is for
- Ebola
- What is being tested?
- V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine and Saline
- Type of treatment
- Vaccines
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 251 participants
- Where
- 1 siteCanada
- Study dates
- 1 Aug 2017to 3 Mar 2023
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- HIV-infected adult or adolescent male or non-pregnant, non-breastfeeding female, ages 13 to 65 (inclusive) at the time of screening;
- On antiretroviral therapy with an undetectable viral load (< 40 c/ml);
- CD4 T cell counts ≥ 200 cells/mm3;
- Written informed consent (subject or parent) and assent (adolescent), after reading the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee
- Free of clinically significant health problems that could affect the safety of the participant, as determined by the Investigator by pertinent medical history and clinical examination prior to entry into the study;
- Available, able, and willing to participate for all study visits and procedures;
Show all 15Show fewer
- Males and females who are willing to practice abstinence from sexual intercourse, or are willing to use effective methods of contraception, from at least 30 days prior to vaccination until 2 months after vaccination.
- If the female partner is NOT of childbearing potential, the couple will only be required to use condoms, without other adjunctive contraception.
- For this study, a woman is considered of childbearing potential unless postmenopausal (≥ 1 year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)
- Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label for example:
- Male condoms PLUS: ii. Oral contraceptives, either combined or progestogen alone iii. injectable progestogen iv. implants of etenogestrel or levonorgestrel v. oestrogenic vaginal ring vi. percutaneous contraceptive patches vii. intrauterine device or intrauterine system
- Be willing to minimize blood and body fluid exposure of others for 6 weeks after vaccination
- Use of effective barrier prophylaxis, such as latex condoms, during penetrative sexual intercourse
- Avoiding the sharing of needles, razors, or toothbrushes
- Avoiding open-mouth kissing
Who cannot join
- History of prior infection with a filovirus or prior participation in a filovirus vaccine trial;
- History of prior infection with VSV or receipt of a VSV-vectored vaccine;
- Is a healthcare worker who has direct contact with patients
- Presence of any febrile illness or any known or suspected acute illness on the day of any first immunization (subject may be rescheduled);
- Clinical manifestations of systemic diseases considered by the investigator to impact safety or immunogenicity
- Receipt of systemic glucocorticoids (a dose ≥ 20 mg/day prednisone or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within six months;
Show all 16Show fewer
- Receipt of any investigational drug within 12 months of vaccination;
- Receipt of any live virus vaccine within 42 days prior to study entry or any other (non-live virus) vaccine within 14 days prior to study entry.
- History of sensitivity to any component of study vaccines per investigator brochure or package insert;
- Any baseline laboratory screening tests which is outside of acceptable range as defined in the protocol: ALT, AST, creatinine, hemoglobin, platelet count, total white blood cell count, urine protein, urine occult blood, urine glucose (Appendix 2). To exclude transient abnormalities, the investigator may repeat a test up to twice, and if the repeat test is normal, subject may be enrolled;
- Have an active malignancy or history of metastatic or hematologic malignancy except non-melanoma skin cancers;
- Suspected or known alcohol and/or illicit drug abuse within the past 5 years;
- Moderate or severe illness and/or fever >101°F (38.3ºC) within one week prior to vaccination;
- Pregnant or breastfeeding female, or female who intends to become pregnant during the study period;
- Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period;
- Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. The study will take place at 2 Canadian sites (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and 2 African sites (Centre MURAZ, Burkina Faso and Centre Hospitalier National Aristide Le Dantec, Dakar, Senegal). The Duration of Study: 365 days for each participant not including screening.
Read the detailed description
The study will enroll approximately 250 participants, ~100 at 2 sites in Canada and ~100 at 2 sites in Africa. Overall ~200 participants will receive the study vaccine and 50 will receive a placebo . Sequential enrollment of five study cohorts will occur over time at each study site according to CD4 T-cell counts: Group 1 will include adult subjects with CD4 ≥ 500 cells/mm3, Group 2 CD4 > 350 and < 500 cells/mm3, Group 3 CD4 ≥ 200 and ≤ 350 cells/mm3, Group 4 adolescents CD4 ≥ 200 cells/mm3, and Group 5 adults and adolescents CD4 ≥ 200 cells/mm3. Enrolment and vaccine administration will begin with the group with the highest CD4 count. When the D42 post-vaccination period is completed for all subjects in Group 1, and the Data Safety Monitoring Board (DSMB) has reviewed the safety data and determined that there are no concerns, enrolment and vaccination of the next CD4 cohort may begin. Similarly, when the D42 safety data for Group 2 has been reviewed/approved by the DSMB, enrolment and vaccination of participants in Group 3 may begin. Adolescents 13-17 years of age (inclusive) with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adults with CD4 ≥ 200. Adolescents 13-17 years of age (inclusive) and adults with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adolescents with CD4 ≥ 200.Within each group, participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the study vaccine or the placebo in a ratio of 4 to 1 (160:40). Participants will complete memory aids for 42 days following vaccination.
Specific procedures to be performed during the trial, as well as their prescribed times and associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each procedure are provided in Section 7.0 - Trial Procedures.
This trial will use an adaptive design based on pre-specified criteria, using an independent, external DSMB to monitor safety and immunogenicity. There will be 3 formal safety analyses performed by the DSMB. Data for at least 75% of participants must be available for each analysis. The first safety analysis will be conducted when the first group (CD4 ≥ 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The second safety analysis will be conducted when the second group (CD4 > 350 and < 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The third safety analysis will be conducted when the third group (Adults CD4 ≥ 200 and ≤ 350 cells/mm3) will have completed 42 days of follow-up post vaccination. The fourth safety analysis will be conducted when the fourth group (Adolescents CD4 ≥ 200) will have completed 42 days of follow-up post vaccination.
Results of the safety analysis will be reviewed by the DSMB, which will make recommendations to the Sponsor to continue, modify or end the trial according to the plan described briefly in Section 2.2 - Trial Diagram and in detail in Section 8.0 - Statistical Analysis Plan. In case of an outbreak of Ebola Zaire the DSMB may recommend to vaccinate subjects randomized to receive placebo with V920 provided at least 84 days of SAE follow-up is conducted.
- Conditions
- Ebola
- Being tested
- V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline
- Medical subject headings
- Hemorrhagic Fever, Ebola
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus VaccineBiological
The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
SalineOther
Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: V920 | Active comparator | Participants randomly assigned to receive ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine. Receives: Biological: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine |
| Group 2: Placebo | Placebo comparator | Participants randomly assigned to receive placebo.
Saline: Normal saline (0.9%) was chosen as an inert substance to serve as placebo control. Receives: Other: Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Solicited Adverse Events Following V920 Vaccination
The number of participants with general solicited local (at the injection site) and systemic adverse events following vaccination will be summarized.
Local AES include: pain at injection site, redness at injection site, swelling at injection site Systemic AEs include: fever, arthritis, arthralgia, rash and blisters/vesicular lesions.
Measured: From vaccine administration up to day 14 following vaccination
Number of Participants With Solicited Adverse Events Following V920 Vaccination
The number of participants with solicited systemic adverse events following vaccination that include arthralgia, blister, joint swelling, pyrexia and rash
Measured: From vaccine administration up to 42 days postvaccination
Number of Participants With Unsolicited Adverse Events Following V920 Vaccination
The number of participants with unsolicited adverse events following vaccination.
These include the following disorders:
Blood and lymphatic system disorders, cardiac disorders, ear and labyrinth disorders, eye disorders, gastrointestinal disorders, general disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, nervous system disorders, psychiatric disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal disorders, skin and subcutaneous tissue disorders,vascular disorders.
Measured: From vaccine administration up to day 42 postvaccination
Number of Participants With Serious Adverse Events Following V920 Vaccination
The number of participants with solicited vaccine-related serious adverse events following V920 vaccination.
Measured: From vaccine administration up to day 365 following vaccination
Geometric Mean Titers Induced by V920
Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits.
Cohorts 1-5.
Measured: Day 28 postvaccination
Geometric Mean Titers Induced by V920
Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits
Only Cohort 5 received 2 doses of vaccine.
Measured: 28 days after LAST (second) dose of vaccine
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2017 (estimated)
- Study start1 Aug 2017
- Primary completion3 Mar 2023
- Study completion3 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for EbolaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 251 participants (actual)
Sponsor and investigators
- Lead sponsor
- Canadian Immunization Research Network
- Sponsor type
- Research network
- Collaborators
- Merck Sharp & Dohme LLC, International Development Research Centre, Canada, Dalhousie University, Université de Montréal, Coalition for Epidemic Preparedness Innovations, University of Ottawa, Centre Muraz, Institute for Health Research - Epidemiological Surveillance and Training (IRESSEF)
- Responsible party
- Principal investigator, Joanne Langley, Canadian Immunization Research Network
- Investigators
- Cecile Tremblay, MD, Principal investigator, CHUM
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03031912
- Sponsor's protocol ID
- CT1401-B
- Status last verified
- Jan 2026
- First submitted
- 22 Dec 2016
- Last updated
- 12 Jan 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tremblay C, Valea I, Ndiaye BP, Barry H, ElSherif M, Cooper C, Breeze JL, Cai Y, Ye L, Omole T, Halperin SA, Mboup S, Langley JM. Safety and immunogenicity of one or two doses of the rVSVDeltaG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet HIV. 2026 Aug 7:S2352-3018(26)00118-9. doi: 10.1016/S2352-3018(26)00118-9. Online ahead of print.
PubMed 42567171